These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31201490)

  • 21. Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression.
    Denault MH; Feng J; Kuang S; Shokoohi A; Leung B; Liu M; Berthelet E; Laskin J; Sun S; Zhang T; Ho C; Melosky B
    Curr Oncol; 2023 Aug; 30(8):7499-7507. PubMed ID: 37623024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
    Flentje M; Huber RM; Engel-Riedel W; Andreas S; Kollmeier J; Staar S; Dickgreber N; Vaissiere N; De Almeida C; Edlich B; Fietkau R
    Strahlenther Onkol; 2016 Apr; 192(4):216-22. PubMed ID: 26809652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.
    Strøm HH; Bremnes RM; Sundstrøm SH; Helbekkmo N; Aasebø U
    Clin Lung Cancer; 2015 May; 16(3):183-92. PubMed ID: 25481662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
    Koshy M; Malik R; Spiotto M; Mahmood U; Rusthoven CG; Sher DJ
    Lung Cancer; 2017 Jun; 108():222-227. PubMed ID: 28625640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salvage Surgery Post Definitive Chemoradiotherapy and Durvalumab for Lung Cancer.
    Minegishi K; Tsubochi H; Ohno K; Komori K; Ozeki M; Endo S
    Ann Thorac Surg; 2021 Jul; 112(1):e53-e55. PubMed ID: 33373589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy.
    Hoffmann M; Reitz D; Taugner J; Roengvoraphoj O; Käsmann L; Eze C; Karin M; Belka C; Manapov F
    Anticancer Res; 2020 Apr; 40(4):2319-2322. PubMed ID: 32234932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR.
    Park CK; Oh HJ; Kim YC; Kim YH; Ahn SJ; Jeong WG; Lee JY; Lee JC; Choi CM; Ji W; Song SY; Choi J; Lee SY; Kim H; Lee SY; Park J; Yoon SH; Joo JH; Oh IJ
    J Thorac Oncol; 2023 Aug; 18(8):1042-1054. PubMed ID: 37085032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience.
    Borghetti P; Volpi G; Facheris G; Cossali G; Mataj E; La Mattina S; Singh N; Imbrescia J; Bonù ML; Tomasini D; Vitali P; Greco D; Bezzi M; Melotti F; Benvenuti M; Borghesi A; Grisanti S; Buglione di Monale E Bastia M
    Front Oncol; 2023; 13():1208204. PubMed ID: 37469420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
    Rajappa S; Sharma S; Prasad K
    Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non-small-cell Lung Cancer Developing After Surgery.
    Nakamichi S; Horinouchi H; Asao T; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ito Y; Watanabe SI; Ohe Y
    Clin Lung Cancer; 2017 Nov; 18(6):e441-e448. PubMed ID: 28583380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial.
    Ko JJ; Banerji S; Blais N; Brade A; Clelland C; Schellenberg D; Snow S; Wheatley-Price P; Yuan R; Melosky B
    Curr Oncol; 2023 Mar; 30(4):3817-3828. PubMed ID: 37185402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting.
    Waterhouse D; Yong C; Frankart A; Brannman L; Mulrooney T; Robert N; Aguilar KM; Ndukum J; Cotarla I
    Future Oncol; 2023 Sep; 19(28):1905-1916. PubMed ID: 37497677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy.
    Matsubara T; Takamori S; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Seto T; Okamoto T
    Thorac Cancer; 2021 Dec; 12(23):3286-3289. PubMed ID: 34689423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer.
    Landman Y; Jacobi O; Kurman N; Yariv O; Peretz I; Rotem O; Dudnik E; Zer A; Allen AM
    Oncoimmunology; 2021; 10(1):1959979. PubMed ID: 34408921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301).
    Atagi S; Mizusawa J; Ishikura S; Takahashi T; Okamoto H; Tanaka H; Goto K; Nakagawa K; Harada M; Takeda Y; Nogami N; Fujita Y; Kasai T; Kishi K; Sawa T; Takeda K; Tomii K; Satouchi M; Seto T; Ohe Y
    Clin Lung Cancer; 2018 Sep; 19(5):e619-e627. PubMed ID: 29887243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of immunotherapy in stage III nonsmall cell lung cancer.
    Wrona A
    Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.